Wugen Raises $172m To Advance NK Cells In Blood Cancers, Solid Tumors

Lead Program Being Tested In AML, Moving Into Other Cancers

 
• By Mandy Jackson
  
business team working on financial data analysis
Wugen raised $36m in seed and series A funding as it worked toward its $172m series B round • Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business